



US007915269B2

(12) **United States Patent**
Davis

(10) **Patent No.:** **US 7,915,269 B2**
(45) **Date of Patent:** ***Mar. 29, 2011**

(54) **METHODS FOR CONCOMITANT
ADMINISTRATION OF COLCHICINE AND A
SECOND ACTIVE AGENT**

(75) Inventor: **Matthew W. Davis**, Erwinna, PA (US)

(73) Assignee: **AR Holding Company, Inc.**,
Wilmington, DE (US)

(*) Notice: Subject to any disclaimer, the term of this
patent is extended or adjusted under 35
U.S.C. 154(b) by 0 days.

This patent is subject to a terminal dis-
claimer.

(21) Appl. No.: **12/858,667**

(22) Filed: **Aug. 18, 2010**

(65) **Prior Publication Data**

US 2010/0305171 A1 Dec. 2, 2010

Related U.S. Application Data

(62) Division of application No. 12/372,046, filed on Feb.
17, 2009, now Pat. No. 7,820,681.

(60) Provisional application No. 61/138,141, filed on Jan.
14, 2009, provisional application No. 61/152,067,
filed on Feb. 12, 2009.

(51) **Int. Cl.**

A61K 31/52 (2006.01)

A61K 31/16 (2006.01)

(52) **U.S. Cl.** **514/263.31**; 514/629

(58) **Field of Classification Search** 514/263.31
See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

5,426,224	A	6/1995	Lee et al.
5,914,332	A	6/1999	Sham et al.
5,968,972	A	10/1999	Broder et al.
6,037,157	A	3/2000	Norbeck et al.
6,245,805	B1	6/2001	Broder et al.
6,896,900	B2	5/2005	Gosselin et al.
7,601,758	B1	10/2009	Davis
7,619,004	B1	11/2009	Davis

OTHER PUBLICATIONS

Creighton et al (Int J STD AIDS 16:362-364, 2005).*

Ogbru and Marks (www.medicinenet.com/colchicine, available
online as of Sep. 8, 2008 and based on FDA Prescribing Informa-
tion).*

Rangno (Management of Gout with Colchicine, available online as of
Jul. 5, 2003).*

Horn et al (Pharmacy Times, May 2006, p. 111).*

Heeswijk et al (AIDS 14:F103-F110, 2000).*

DRUGS.COM; "colchicine and ritonavir interactions", printed Jan.
5, 2009; "colchicine", printed Jan. 9, 2009; and "ritonavir", printed
Jan. 9, 2009.

Horn, et al.; "Life-Threatening Colchicine Drug Interactions"; Phar-
macy Times; pp. 111; (May 2006).

Hsu, et al.; "Ritonavir; Clinical Pharmacokinetics and Interactions
with Other Anti-HIV Agents"; Clinical Pharmacokinetics; 35; pp. 275-
291; (1998).

Niel, et al.; "Colchicine Today"; Joint Bone Spine; 73; pp. 672-678;
(2006).

Perez-Ruiz, et al.; "Optimisation of the Treatment of Acute Gout";
BioDrugs; 13; pp. 415-423; (2000).

Terkeltaub, Robert A.; "Gout"; The New England Journal of Medi-
cine; 349; pp. 1647-1655; (2003).

Van Der Velden, et al.; "Colchicine-Induced Neuromyopathy in a
Patient With Chronic Renal Failure: The Role of Clarithromycin";
Netherlands, The Journal of Medicine; 66; pp. 204-206; (2008).

Zhou, et. al.; "Clinical Outcomes and Management of Mechanism-
Based Inhibition of Cytochrome P450 3A4"; Therapeutics and Clinical
Risk Management; 1; pp. 3-13; (2005).

Drugs.com; "Colchicine Dosage" (available online <http://www.drugs.com/dosage/colchicine.html>); 6 pages; accessed Sep. 20,
2010.

Rx-s.net/weblog/more/colchicine-indications-and-dosage/;

"Colchicine Indications and Dosage"; 5 pages; last revised Aug. 2,
2005.

U.S. Appl. No. 12/858,754, filed Aug. 18, 2010; Non-Final Office
Action dated Oct. 5, 2010; 38 pages.

Achter et al. "Pharmacokinetics/bioavailability of colchicine in
healthy male volunteers" Eur. J. Drug Metab. Pharmacokinetics. 1989,
14(4): 317-322.

FDA; "Drugs"; Questions and Answers About FDA's Enforcement
Action Against Unapproved Injectable Colchicine Products"; <http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/EnforcementAction/>; printed Dec. 6, 2010.

FDA; "In Vivo Drug Metabolism/Drug Interaction Studies—Study
Design, Data Analysis, and Recommendations for Dosing and Label-
ing"; Nov. 1999 (:FDA Guidance) 19 pages.

Sabourand, et al.; "Pharmacokinetics of Colchicine. A review of
Experimental and Clinical Data"; 2 Gastroenterol (Suppl. 1)30: pp.
35-39; (1992).

U.S. Appl. No. 12/372,046, filed Feb. 17, 2009; Non-Final Office
Action dated Jan. 26, 2010, 30 pages.

U.S. Appl. No. 12/372,046, filed Feb. 17, 2009; Non-Final Office
Action dated May 18, 2009; 9 pages.

U.S. Appl. No. 12/372,046, filed Feb. 17, 2009; Final-Office Action
dated Sep. 11, 2009; 10 pages.

U.S. Appl. No. 12/372,046, filed Feb. 17, 2009; Non-Final Office
Action dated Jul. 14, 2009; 10 pages.

U.S. Appl. No. 12/688,038, filed Jan. 15, 2010; Final Office Action
dated Jun. 28, 2010; 33 pages.

U.S. Appl. No. 12/688,038, filed Jan. 15, 2010; Non-Final Office
Action dated Apr. 2, 2010; 36 pages. Colchicine-Probenecid,
Colchicine-Probenecid—Side effect guide, warning symptoms;
<http://www.healthgrades.com/drug-ratings/drug/sideeffects/2207/>
Colchicine-Probenecid; printed Dec. 2, 2009; 2 pages.

COLCYRS, Prescribing Information, www.colcrys.com/assets/pdf/COLCRYR-Full-Prescribing-Information.pdf; pp. 1-5; revised Sep.
2009; printed Oct. 19, 2009.

Herewege, et al; A Dual Chamber Model of Female Cervical
Mucosa for the Study of HIV Transmission and for the Evaluation of
Candidate HIV Microbicides; Antiviral Research; 74; pp. 111-124;
(2007).

(Continued)

Primary Examiner — Brandon J Fetterolf

Assistant Examiner — Craig Ricci

(74) *Attorney, Agent, or Firm* — Cantor Colburn LLP

(57)

ABSTRACT

Methods for concomitant administration of colchicine
together with one or more second active agents, e.g., keto-
conazole and ritonavir, are disclosed. Such methods reduce
the dangers commonly associated with such concomitant
administration and provide additional benefits. Methods of
notifying health care practitioners and patients regarding
appropriate dosing for concomitant administration of colchi-
cine together with second active agents are also provided.

1 Claim, 5 Drawing Sheets